EkoSonic™ Endovascular System

Ultrasonic Technology

Control Unit

Clinical Evidence

Reimbursement
EKOS Ultrasound Guided Catheter directed thrombolysis for the treatment of pulmonary embolism.
EkoSonic - The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
The EkoSonic catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.
EKOS Ultrasound Guided Catheter directed thrombolysis for the treatment of pulmonary embolism.
EkoSonic - The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
The EkoSonic catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.
EKOS Ultrasound Guided Catheter directed thrombolysis for the treatment of pulmonary embolism.
EkoSonic - The targeted ultrasound waves differentiate this technology, providing accelerated clot dissolution by unwinding the fibrin matrix.
The EkoSonic catheter is comprised of two parts: the Infusion catheter and the ultrasonic core.

EKOS was the first product indicated for the treatment of pulmonary embolism. The EkoSonic catheter can be used for the infusion of physician selected therapeutics, including thrombolytics into the peripheral vasculature.

Key Resources

EkoSonic Indications, Safety, and Warnings EkoSonic System Brochure Reimbursement Information
Sign-Up for Product Updates

Product Description

EKOS therapy is a minimally invasive system for dissolving thrombus. The ultrasonic core generates an acoustic field which greatly accelerates lytic dispersion by driving the drug deeper into the clot and unwinding the fibrin to expose plasminogen receptor sites. 

Acoustic Pulse Thrombolysis™

  • Speeds time-to-clot dissolution.
  • Results in quality clinical outcomes.
  • Increases clot removal and enhances clinical improvement compared to either standard catheter-directed drug therapy or thrombectomy.1,2
  • Requires significantly shorter treatment times compared to standard CDT.3

Targets the Thrombus Safely

  • Lowers the risk of bleeding and other complications.1,4
  • Dissolves clots without damaging vessels, valves or walls.5

More Effective Drug Delivery

  • Reduces dosage requirements by as much as 68% compared to standard, catheter-directed drug therapy.1
  • Requires up to 4x less drug dosage than traditional systemic delivery.6,7
  • Reduces RV/LV ratio with as little as 8mg total tPA used in combination with EKOS therapy.8

Superior Clot Clearance3,7

  • 48% greater drug absorption within 1 hour.9
  • 84% greater drug absorption within 2 hours. 9
  1. Lin, P., et al., Vasc, Vol. 17, Suppl. 3, 2009, S137-S147.
  2. Lin, P., et al., Perspectives in Vasc Surg and Endo Ther, 2010, 22(3):152-163.
  3. Litzendorf, M., et al., SVS 2011 Abstract RR20.
  4. Parikh, S., et al., J Vasc Interv Radiol, Vol. 19, Issue 4, April 2008, 521–528.
  5. Soltani, A et al. Ultrasonics 2007; 46:60-67.
  6. Kucher, N., et al., Circulation, Vol. 129, No. 4, 2014, 479–486.
  7. Piazza, G., et al., JACC: Cardiovasc Intervent 2015; 8(10): 1382-92.
  8. Tapson, Victor, et al., “A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial.” JACC: Cardiovascular Interventions Jul 2018, 11 (14) 1401-1410.
  9. Francis, C.W., et al., Ultrasound in Medicine and Biology, 21.3, 1995, 419–424.

 

Reimbursement Information

The C-Code used for the EkoSonic™ Endovascular System is C1757. C-Codes are used for hospital outpatient device reporting for Medicare and some private payers. Note: Boston Scientific Corporation is not responsible for correct use of codes on submitted claims; this information does not constitute reimbursement or legal advice.
Learn more about EKOS reimbursement
Top